Barbara Botto
-
- Lymphoma Diagnosis and Treatment 54
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 19
- Neurology top 5%
- CNS Lymphoma Diagnosis and Treatment 28
- Oncology top 5%
- Viral-associated cancers and disorders 16
- CAR-T cell therapy research 8
-
- Lung Cancer Treatments and Mutations 8
-
- Multiple Myeloma Research and Treatments 3
-
- Cutaneous lymphoproliferative disorders research 3
- Co-authors
- Umberto VitoloRoberto FreiloneM BertiniLorella OrsucciLuigi RigacciPier Luigi ZinzaniL ResegottiFrancesco Merli
- Partner nations
- ItalyUnited StatesSwitzerland
In The Last Decade
Barbara Botto
56 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 65
- Pathology and Forensic Medicine 1.1k
- Genetics 334
- Neurology 435
- Oncology 571
- Radiology, Nuclear Medicine and Imaging 301
Countries citing papers authored by Barbara Botto
This map shows the geographic impact of Barbara Botto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Botto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Botto more than expected).
Fields of papers citing papers by Barbara Botto
This network shows the impact of papers produced by Barbara Botto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Botto. The network helps show where Barbara Botto may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Barbara Botto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 3 | |
| 5 | 2023 | 6 | |
| 6 | 2021 | 3 | |
| 7 | 2019 | 18 | |
| 8 | 2019 | 3 | |
| 9 | 2019 | 29 | |
| 10 | 2018 | 3 | |
| 11 | 2017 | 23 | |
| 12 | 2017 | 1 | |
| 13 | 2016 | 16 | |
| 14 | 2012 | 23 | |
| 15 | SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL. | 2011 | 1 |
| 16 | 2000 | 9 | |
| 17 | 1998 | 79 | |
| 18 | 1997 | 52 | |
| 19 | 1996 | 32 | |
| 20 | 1996 | 50 |
About Barbara Botto
Barbara Botto is a scholar working on Pathology and Forensic Medicine, Genetics and Neurology, having authored 60 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (54 papers), CNS Lymphoma Diagnosis and Treatment (28 papers), Chronic Lymphocytic Leukemia Research (19 papers), Viral-associated cancers and disorders (16 papers), CAR-T cell therapy research (8 papers), Lung Cancer Treatments and Mutations (8 papers), Multiple Myeloma Research and Treatments (3 papers) and Cutaneous lymphoproliferative disorders research (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.1k citations), Genetics (334 citations) and Neurology (435 citations). Barbara Botto has collaborated with scholars based in Italy, United States and Switzerland. Frequent co-authors include Umberto Vitolo, Roberto Freilone, M Bertini, Lorella Orsucci, Luigi Rigacci, Pier Luigi Zinzani, L Resegotti, Francesco Merli, Alessandro Levis and Silvia Franceschetti. Their work appears in journals such as Blood, British Journal of Haematology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.